NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) represent some of the most complex and therapeutically challenging disorders in modern medicine. Despite decades of research, the traditional one drug-one target paradigm has largely failed to deliver disease-modifying therapies. Increasing evidence suggests that these complex diseases arise from interconnected pathological networks involving protein aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, and synaptic loss. In this context, natural products (NPs) have re-emerged as a promising pipeline for next-generation therapeutics. Unlike conventional small molecules, NPs inherently exhibit polypharmacology, targeting multiple pathways simultaneously. Recent advances (2019-2026) demonstrate a paradigm shift, from crude NPs and single-mechanism compounds toward engineered derivatives, network pharmacology, and multi-target drug design. Using AD and PD as case studies, this review critically evaluates how NPs are redefining drug discovery by highlighting key emerging NPs, translational strategies, and future directions.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.